



August 15, 2022

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, DC 20549-3720

Attention: Joshua Gorsky

Re: **Tenaya Therapeutics, Inc. Registration Statement on Form S-3**  
**Filed August 10, 2022**  
**File No. 333-266741**

**Acceleration Request**

**Requested Date: August 17, 2022**

**Requested Time: 4:00 P.M. Eastern Time, or as soon thereafter as practicable**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Tenaya Therapeutics, Inc. (the "**Company**") hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-266741) (the "**Registration Statement**") be declared effective at the "Requested Date" and "Requested Time" set forth above, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Jennifer Knapp at (650) 849-3041.

Please direct any questions or comments regarding this acceleration request to Jennifer Knapp at (650) 849-3041.

*[Signature page follows]*

Sincerely,

TENAYA THERAPEUTICS, INC.

/s/ Leone D. Patterson, M.B.A.

Leone D. Patterson, M.B.A.

*Chief Financial and Business Officer*

cc: Jennifer Drimmer Rokovich, J.D., Tenaya Therapeutics, Inc.  
Jennifer Knapp, Wilson Sonsini Goodrich & Rosati, P.C.